ANSES DG Delegates Authority, Streamlining French Regulatory Approvals
ANSES Director-General has delegated signing authority to key personnel, a move expected to expedite administrative processes for supplement product approvals and compliance documentation within France.
Paris, France — 25 August 2026
The French Agency for Food, Environmental and Occupational Health & Safety (ANSES) has announced a significant internal restructuring of its administrative authority. Decision n° 2026-141, signed by the Director-General, formally delegates signatory powers to specific internal executives. This delegation of authority primarily affects the validation and approval stages of regulatory dossiers, including those pertaining to food supplements.
Historically, the centralisation of final signatory approval at the Director-General level could introduce bottlenecks, extending the time-to-market for novel ingredients or product reformulations. The new decision aims to streamline these processes by empowering more departmental heads to sign off on specific regulatory clearances, scientific opinions, and administrative decisions. For the supplement sector, this includes areas such as ingredient novel food applications, health claims assessments, and product notification validations, which fall under ANSES's remit for public health safety.
While the exact individuals and their delegated scope are not publicly detailed in the high-level announcement, the functional impact is clear: a decentralised, and therefore potentially faster, approval chain. This move signals an intent to improve the efficiency of regulatory oversight without compromising the rigour of scientific assessment. Industry operators should interpret this as a push for greater responsiveness from the French regulator.
However, increased speed also implies reduced tolerance for incomplete or inaccurate submissions. Dossiers that previously might have seen extended back-and-forth communication for minor corrections could now face swifter rejection if not fully compliant from the outset. Manufacturers must ensure their regulatory affairs teams are fully aligned with current ANSES guidelines to capitalise on these potential efficiency gains.
What this means for France
French manufacturers and brand owners can anticipate accelerated processing for new product notifications and ingredient approvals, potentially reducing market entry delays by several weeks. Regulatory teams must now focus on submitting 'right first time' dossiers, as delegated authorities may enforce stricter adherence to guidelines, bypassing the protracted dialogue common with centralised approvals. This shift offers a competitive edge for brands capable of rapid, compliant dossier preparation, allowing for quicker market launches and faster capitalisation on emerging consumer trends. Procurement leads should assess supplier capabilities for generating compliant documentation to leverage these faster approval cycles in France.
Many leading brands in this category are manufactured in partnership with Supplement Factory.